Phase I Study of Immunotoxin in Patients
Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Patients With Advanced Malignancies
That Express Mesothelin
Background:
Immunotoxins can locate tumor cells and kill them without harming normal cells.
Immunotoxin therapy may be an effective treatment for advanced cancer. This is a
Phase I trial to study the effectiveness of immunotoxins in treating patients who
have advanced cancer.
Location/Contacts:
Maryland
Bethesda
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Patient Recruitment
Ph: 301-496-4891
1-888-NCI-1937
